Statin Pharmacogenetics in Metabolic Syndrome

Metabolic syndrome is a modern era disease which has engulfed wide regions of the world and the problem is increasing at a rapid pace. The atherogenic dyslipidemia associated with the metabolic syndrome predispose to cardiovascular events. The Statins are considered first-line therapy for treating Dyslipidemia. Clinical response to statins is highly variable and genetic factors play an important role. Sterol regulatory element binding factors (SREBF) SREBF Cleavage Activating Protein (SCAP) pathway play important roles in lipid metabolism and homeostasis. Identification of genes & genetic variants that influence statin responsiveness holds promise for a safe and effective treatment of Dyslipidemia in Metabolic syndrome.

Autorentext

Dr Misbahuddin is a medical pharmacologist from India. After MBBS and MD, he joined as junior faculty at Aligarh Muslim University. Then he joined King Abdulaziz University, Saudi Arabia as an Assistant Professor. Dr Misbahuddin has a number of publications to his credit and has participated at various national & international scientific events